On this page
Hypertriglyceridaemia
Also known as High triglycerides · Raised triglycerides
For most people, raised triglycerides are not caused by one rare, high-impact gene fault. Instead, dozens to hundreds of common DNA variants - each with a tiny individual effect - add together and interact with diet, weight, alcohol and conditions such as type 2 diabetes. This cumulative genetic burden shifts a person's average triglyceride level upwards and explains why the trait runs in families without a clear single-gene pattern.
Available at Jeen Health
Clinical tests that include this
Overview
Hypertriglyceridaemia means an above-normal level of triglycerides, the main type of fat carried in the blood. It is usually defined as a fasting level of 1.7 mmol/L or more, with mild (1.7-2.3 mmol/L) and moderate-to-severe categories above that. It is one of the most common lipid abnormalities: international studies report that raised triglycerides affect somewhere between roughly 18% and 33% of adults, and a figure of around 1 in 5 UK adults is a reasonable working estimate, closely tracking rates of obesity and type 2 diabetes. The condition often causes no symptoms and is picked up on a routine cholesterol or lipid blood test. It matters because raised triglycerides are linked to a higher risk of cardiovascular disease, and very high levels (above about 10 mmol/L) sharply increase the risk of acute pancreatitis. Most cases are multifactorial, reflecting genetic predisposition combined with lifestyle and other health conditions.
Symptoms & clinical features
Hypertriglyceridaemia itself is usually silent and is most often discovered through a blood test rather than because of symptoms. When levels become very high, fatty deposits called xanthomas can appear under the skin, the retina's blood vessels may take on a pale, creamy look (lipaemia retinalis), and people can develop episodes of severe upper abdominal pain from acute pancreatitis. Raised triglycerides frequently travel alongside other features of metabolic syndrome - central weight gain, raised blood pressure, low HDL cholesterol and raised blood sugar. Importantly, having a high polygenic risk does not change how the condition presents or feels. The genetic score reflects an increased likelihood of developing raised triglycerides over time; it does not produce its own symptoms and does not alter the clinical picture once the condition is present.
Video: Genetics 101
Affected organs
Triglycerides circulate in the bloodstream, so hypertriglyceridaemia is fundamentally a disorder of lipid metabolism affecting the cardiovascular system and the blood vessels. The liver, which produces and clears triglyceride-rich lipoproteins, is central to the process and can accumulate fat. When levels are very high, the pancreas is at particular risk, as severe hypertriglyceridaemia is a recognised trigger for acute pancreatitis. The condition also commonly involves wider metabolic systems linked to insulin resistance.
Risks & severity
A polygenic risk score is usually expressed as a percentile - for example, being in the top 10% or 20% for inherited triglyceride predisposition - or as a relative risk compared with people of average genetic risk. It describes a shift in likelihood across a population, not a guarantee: many high-percentile people will never develop notably raised triglycerides, and some lower-percentile people will, because lifestyle and other conditions matter so much. A crucial limitation is that predictive performance varies by condition and, particularly, by genetic ancestry. Most scores were developed largely in people of European ancestry and tend to predict less accurately in other populations, so results should be interpreted with appropriate caution and always alongside actual blood measurements and clinical assessment.
Genetic causes
Common, mild-to-moderate hypertriglyceridaemia is overwhelmingly polygenic. Genome-wide association studies, including the large Global Lipids Genetics Consortium, have identified dozens of common variants robustly associated with blood triglyceride levels - well over thirty established loci, with later analyses pointing to many more. Among the best-established are variants near or within APOA5, LPL, GCKR, APOB, APOE, TRIB1, MLXIPL/TBL2, ANGPTL3 and GALNT2. Each variant shifts triglyceride levels by only a small amount, and some minor alleles raise levels while others lower them; it is the net sum across the genome that counts. These same common variants that drive small differences within the normal range also contribute substantially to clinically raised triglycerides, and they can amplify the effect of rare variants when both are present. This many-small-effects architecture is captured by a polygenic risk score, which aggregates the individual contributions into a single estimate of inherited predisposition.
Inheritance pattern
Polygenic hypertriglyceridaemia does not follow the clear-cut Mendelian patterns seen in single-gene disorders, where a fault is passed on in a predictable dominant or recessive way. Instead, each parent passes on a random mixture of the many common triglyceride-influencing variants they carry. A child inherits some higher-raising and some lower-raising variants, and their overall genetic predisposition sits somewhere on a continuous distribution across the population - most people in the middle, fewer at the extremes. This is why raised triglycerides cluster in families without a tidy inheritance pattern, and why two siblings can have quite different genetic risk. Inherited predisposition is only part of the story: diet, alcohol, body weight, physical activity and conditions such as diabetes strongly modify whether that genetic tendency translates into measurably raised levels.
Diagnosis & testing
A polygenic risk score is a risk estimate, not a diagnosis. Hypertriglyceridaemia itself is diagnosed simply by measuring triglycerides in a blood sample, usually as part of a lipid profile and often after fasting. A polygenic risk score works differently: it reads many common variants across a person's genome, weights each by its known effect on triglyceride levels, and sums them into a single number indicating how that person's inherited predisposition compares with others. The score can flag someone as having above-average genetic susceptibility before triglycerides have risen, but it cannot tell you a person's current level, confirm that they have the condition, or replace a blood test. A high score should prompt confirmatory lipid testing and a wider assessment of cardiovascular and metabolic risk rather than standing alone.
Management & lifestyle
There is no specific treatment for a polygenic risk score; the value lies in earlier awareness and prevention. For someone with elevated genetic risk, the priorities are checking actual triglyceride levels and addressing modifiable factors, because lifestyle has a large influence on this trait. UK guidance emphasises a healthy diet, reducing refined sugars and alcohol, achieving a healthy weight, increasing physical activity and managing conditions such as type 2 diabetes that drive triglycerides up. Where levels are persistently raised, a GP will assess overall cardiovascular risk; statins are first-line where indicated, and fibrates or omega-3 preparations may be considered, particularly when triglycerides are very high and there is a risk of pancreatitis. NICE notes that standard risk calculators may underestimate cardiovascular risk when triglycerides are between 4.5 and 9.9 mmol/L. Acting early on a high score means tighter lifestyle attention and more timely lipid monitoring.
UK care pathway
In the NHS, triglycerides are measured as part of routine lipid testing rather than through a dedicated screening programme. They are commonly checked during an NHS Health Check (offered to adults aged 40-74 in England), when assessing cardiovascular risk, or when investigating diabetes, pancreatitis or other concerns. Management is led in primary care, guided by NICE recommendations on lipid modification and cardiovascular risk. People with very high or treatment-resistant triglycerides may be referred to a specialist lipid clinic. There is no routine NHS polygenic risk testing for triglycerides at present.
Frequently asked questions
How is polygenic triglyceride risk different from a single-gene fault?
A single-gene fault, such as the rare familial chylomicronaemia syndrome, involves one or two high-impact mutations that on their own cause extremely high triglycerides, usually from childhood and following a clear inheritance pattern. Polygenic risk is completely different: it comes from the combined effect of many common variants, each making only a tiny contribution. No single one causes the condition, but together they shift a person's average triglyceride level and overall susceptibility. This is why polygenic risk is described as a continuous tendency rather than a yes/no diagnosis.
Is polygenic risk scoring for triglycerides available on the NHS?
Not routinely. The NHS measures triglycerides through standard blood tests - for example during an NHS Health Check or when assessing cardiovascular and metabolic risk - but it does not currently offer polygenic risk scoring for triglycerides as part of normal care. Polygenic scores are mainly available through research studies and private services such as Jeen Health. Any result should be discussed with your GP and confirmed with an actual lipid blood test, not used in place of NHS testing.
If I have a high polygenic score, will I definitely develop high triglycerides?
No. A high score means your inherited predisposition is above average, not that the condition is certain. Triglyceride levels are strongly shaped by diet, alcohol, body weight, physical activity and conditions such as type 2 diabetes, so many people with a high score keep normal levels through lifestyle, while some with a lower score still develop raised triglycerides. The score shifts the odds; it does not determine your outcome.
What should I actually do if my triglyceride polygenic risk is elevated?
Treat it as an early prompt rather than a diagnosis. Sensible steps are to have your actual triglyceride and cholesterol levels checked, and to focus on the factors you can change: a healthy diet lower in refined sugar and alcohol, reaching a healthy weight, staying active and managing any diabetes. Share the result with your GP, who can assess your overall cardiovascular risk and arrange appropriate monitoring or treatment if your measured levels are raised.
References
- Goto T, Ishizuka K, Kitai Y. Hypertriglyceridaemia-induced pancreatitis. QJM : monthly journal of the Association of Physicians. 2023. PMID: 37052536
- Laufs U, Parhofer KG, Ginsberg HN. Clinical review on triglycerides. European heart journal. 2020. PMID: 31764986
- Ryan A, Simpson WG, Twomey P. Hypertriglyceridaemia: a commentary. Journal of clinical pathology. 2023. PMID: 36167730
- Pintó X, Fanlo M, Esteve V. Remnant cholesterol, vascular risk, and prevention of atherosclerosis. Clinica e investigacion en arteriosclerosis : publicacion oficial de la Sociedad Espanola de Arteriosclerosis. 2023. PMID: 36889989
- Mikhailidis D, Ganotakis E, Georgoulias V. Tamoxifen-induced hypertriglyceridaemia. Oncology reports. 1997. PMID: 21590112
- Pérez-Martínez P, Pérez-Jiménez F. Treatment of mild-to-moderate hypertriglyceridemia. Clinica e investigacion en arteriosclerosis : publicacion oficial de la Sociedad Espanola de Arteriosclerosis. 2021. PMID: 34006357
- Qiu M, Zhou X, Zippi M. Comprehensive review on the pathogenesis of hypertriglyceridaemia-associated acute pancreatitis. Annals of medicine. 2023. PMID: 37813108
- Hegele RA, Ginsberg HN, Chapman MJ. The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management. The lancet. Diabetes & endocrinology. 2014. PMID: 24731657